Market research
TFFP Tff Pharmaceuticals Inc
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 289K
- P/E ratio
- Not available
- Analyst target
- 30
- Dividend yield
- Not available
- Beta
- 1.32
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US87241J1043
- Market cap
- 289K
- P/E ratio
- Not available
- Analyst target
- 30
- Dividend yield
- Not available
- Beta
- 1.32
About
About Tff Pharmaceuticals Inc
TFF Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing drug products based on its patented Thin Film Freezing (TFF) technology platform in the United States and Australia. It intends to focus on the development of inhaled dry powder drugs for the treatment of pulmonary diseases and conditions. The company's drug candidates are TFF Voriconazole Inhalation Powder, which is in Phase II clinical trials for the treatment and prophylaxis of invasive pulmonary aspergillosis; and TFF Tacrolimus Inhalation Powder, which is in Phase II clinical trials used to prevent lung transplant rejection. It also develops other dry powder products, such as Augmenta human derived monoclonal antibodies for the treatment of COVID-19 disease; and other vaccines. It has a license agreement with the University of Texas at Austin for the development of inhaled dry powder drugs. TFF Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Fort Worth, Texas.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the TFFP discussion.
5 years, 4 months ago
TFF Pharmaceuticals, Inc is currently in a long term downtrend where the price is trading 30.7% below its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
TFF Pharmaceuticals, Inc's total revenue sank by nan% to $0 since the same quarter in the previous year.
Its net income has dropped by 26.5% to $-6M since the same quarter in the previous year.
Finally, its free cash flow fell by 63.5% to $-7M since the same quarter in the previous year.
Based on the above factors, TFF Pharmaceuticals, Inc gets an overall score of 1/5.